Bayer plans £8bn spending spree
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Bayer, the German chemicals giant, will spend £8bn over the next three years to strengthen its position as one of the world's leading chemical companies, Manfred Schneider, its chief executive, said yesterday.
Spread over research and capital investment, some of the war chest will be used for acquisitions to reinforce Bayer's operations in selected sectors. One-fifth of expenditure will be in the US, with Asia the other priority region.
Mr Schneider said the aim was to increase worldwide sales in the medium-term from the current equivalent of £17bn to more than £21bn, and the return on sales to at least 10 per cent.
After a bumpy ride through the recession, Bayer is enjoying a surge in profits as it benefits from the stronger economic environment and a radical rationalisation programme.
Pre-tax profits for 1994 are expected to reach £1.3bn, and Mr Schneider expressed confidence that both sales and earnings would increase in the current year.
He indicated that Bayer intended to expand its activities in the US still further after last year's purchase for £650m of the North American over-the-counter business of Sterling Winthrop. The US market held a very promising future for the group, he said.
Late last year, Mr Scheider confirmed Bayer was in negotiations for a further takeover, and was planning an important co-operative venture, both of which were expected to be completed in early 1995. He said then that there were no plans for acquisitions in pharmaceuticals.
Yesterday, he focused on what he called the significant opportunities to be found in the businesses covering pharmaceuticals, consumer care and diagnostics. The goal was to increase the contribution of this segment to total group sales from a current 26 per cent to 30 per cent by 2000.
Mr Schneider was yesterday introducing the Bayer group to the US media following the acquisition of Sterling Winthrop, which also gave the German company back the rights to its name and trademarks. These had been confiscated and sold to Sterling after the First World War.
Bayer's US subsidiary, Miles Inc, will be renamed Bayer Corporation on 1 April.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments